Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 8 September 2026Incoming appointee
1 itemScheduled Appointment Date1 October 2026
Imagawa Kuniaki (今川 国明)
Previous positionManaging Director, in charge of the Pharmaceutical Business, and Representative Director and President of Mediceo Corporation
New positionRepresentative Director and President, and Representative Director and Chairman of Mediceo Corporation
生年月日 10 September 1961入社年 1984所有株式数 10,000 shares (as of 31 March 2026)
Departing officer
1 itemWatanabe Shuichi (渡辺 秀一)Next role stated
Former PositionRepresentative Director and President, with responsibility for Group Compliance, and Director and Senior Adviser of Mediceo Corporation
New positionRepresentative Director and Chairman, with responsibility for Group Compliance
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Will remain on the Board of Directors as Representative Director and Chairman
Reason for change
To further enhance the corporate value and achieve sustainable growth of the Company and the Group under the new management structure.
| Item | Details |
|---|---|
| Resolution date | 8 September 2026 |
| Scheduled Appointment Date | 1 October 2026 |
| Name of appointee | Imagawa Kuniaki (今川 国明) |
| Appointee's new position | Representative Director and President, and Representative Director and Chairman of Mediceo Corporation |
| Appointee's previous position | Managing Director, in charge of the Pharmaceutical Business, and Representative Director and President of Mediceo Corporation |
| Appointee's date of birth | 10 September 1961 |
| Year the appointee joined the Company | 1984 |
| Number of shares held by the appointee | 10,000 shares (as of 31 March 2026) |
| Name of departing officer | Watanabe Shuichi (渡辺 秀一) |
| Former position of departing officer | Representative Director and President, with responsibility for Group Compliance, and Director and Senior Adviser of Mediceo Corporation |
| New position of departing officer | Representative Director and Chairman, with responsibility for Group Compliance |
| Whether the incumbent will remain in office | Will remain on the Board of Directors as Representative Director and Chairman |
| Reason for change | To further enhance the corporate value and achieve sustainable growth of the Company and the Group under the new management structure. |
Items this document does not state (8)
Date of departureReason for departureReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To further enhance the corporate value and achieve sustainable growth of the Company and the Group under the new management structure.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.